| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fragile X Syndrome | 82 | 2018 | 83 | 15.560 |
Why?
|
| Fragile X Mental Retardation Protein | 43 | 2018 | 43 | 3.830 |
Why?
|
| Humans | 150 | 2018 | 2210 | 3.660 |
Why?
|
| Tremor | 22 | 2018 | 22 | 3.280 |
Why?
|
| Ataxia | 20 | 2018 | 20 | 3.220 |
Why?
|
| Male | 105 | 2017 | 1214 | 2.950 |
Why?
|
| Female | 98 | 2017 | 1137 | 2.880 |
Why?
|
| Mutation | 37 | 2017 | 63 | 2.040 |
Why?
|
| Cognition Disorders | 14 | 2016 | 67 | 2.000 |
Why?
|
| Adult | 54 | 2017 | 681 | 1.910 |
Why?
|
| Transcription Factors | 27 | 2016 | 33 | 1.880 |
Why?
|
| Child | 40 | 2017 | 161 | 1.870 |
Why?
|
| Homeodomain Proteins | 26 | 2016 | 26 | 1.810 |
Why?
|
| Heterozygote | 18 | 2016 | 22 | 1.660 |
Why?
|
| Adolescent | 34 | 2017 | 218 | 1.520 |
Why?
|
| Sleep Apnea, Central | 16 | 2016 | 16 | 1.520 |
Why?
|
| Hypoventilation | 18 | 2016 | 19 | 1.500 |
Why?
|
| Sudden Infant Death | 13 | 2013 | 17 | 1.470 |
Why?
|
| Phenotype | 25 | 2016 | 50 | 1.400 |
Why?
|
| Child, Preschool | 31 | 2017 | 91 | 1.330 |
Why?
|
| Trinucleotide Repeat Expansion | 13 | 2016 | 13 | 1.270 |
Why?
|
| Genetic Predisposition to Disease | 18 | 2016 | 42 | 1.160 |
Why?
|
| Autism Spectrum Disorder | 3 | 2017 | 3 | 1.150 |
Why?
|
| Epilepsy | 6 | 2017 | 7 | 1.110 |
Why?
|
| Neurodevelopmental Disorders | 2 | 2017 | 2 | 1.080 |
Why?
|
| Animals | 34 | 2017 | 734 | 1.050 |
Why?
|
| Infant | 30 | 2017 | 89 | 0.990 |
Why?
|
| Genetic Testing | 9 | 2016 | 10 | 0.980 |
Why?
|
| Clinical Trials as Topic | 6 | 2017 | 22 | 0.890 |
Why?
|
| Autonomic Nervous System Diseases | 11 | 2016 | 11 | 0.880 |
Why?
|
| Treatment Outcome | 14 | 2016 | 232 | 0.880 |
Why?
|
| Brain | 19 | 2015 | 92 | 0.820 |
Why?
|
| Neuropsychological Tests | 16 | 2016 | 112 | 0.810 |
Why?
|
| Genetic Carrier Screening | 8 | 2017 | 8 | 0.810 |
Why?
|
| Young Adult | 22 | 2017 | 209 | 0.780 |
Why?
|
| Trinucleotide Repeats | 7 | 2018 | 7 | 0.780 |
Why?
|
| Niemann-Pick Disease, Type C | 3 | 2017 | 3 | 0.760 |
Why?
|
| Aged | 31 | 2016 | 490 | 0.750 |
Why?
|
| Alzheimer Disease | 8 | 2014 | 91 | 0.730 |
Why?
|
| Autistic Disorder | 5 | 2014 | 5 | 0.730 |
Why?
|
| Middle Aged | 28 | 2017 | 608 | 0.720 |
Why?
|
| Neurotransmitter Agents | 3 | 2017 | 3 | 0.690 |
Why?
|
| Mice | 23 | 2015 | 208 | 0.680 |
Why?
|
| Receptors, Metabotropic Glutamate | 6 | 2012 | 6 | 0.670 |
Why?
|
| Nerve Tissue Proteins | 17 | 2011 | 27 | 0.670 |
Why?
|
| Neonatal Screening | 3 | 2017 | 3 | 0.650 |
Why?
|
| Genetic Therapy | 5 | 2016 | 16 | 0.650 |
Why?
|
| Behavior | 3 | 2016 | 5 | 0.630 |
Why?
|
| Genetic Counseling | 4 | 2016 | 4 | 0.620 |
Why?
|
| Severity of Illness Index | 6 | 2016 | 62 | 0.620 |
Why?
|
| Indoles | 2 | 2016 | 7 | 0.600 |
Why?
|
| Alleles | 18 | 2017 | 27 | 0.590 |
Why?
|
| Mental Disorders | 2 | 2016 | 16 | 0.590 |
Why?
|
| Neurons | 11 | 2015 | 42 | 0.580 |
Why?
|
| RNA, Messenger | 10 | 2018 | 38 | 0.540 |
Why?
|
| Adaptation, Psychological | 2 | 2017 | 9 | 0.530 |
Why?
|
| Gait | 2 | 2016 | 18 | 0.530 |
Why?
|
| Developmental Disabilities | 5 | 2017 | 7 | 0.520 |
Why?
|
| Case-Control Studies | 19 | 2015 | 65 | 0.520 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2014 | 19 | 0.520 |
Why?
|
| Disease Management | 1 | 2016 | 10 | 0.520 |
Why?
|
| Enzyme Replacement Therapy | 1 | 2016 | 1 | 0.520 |
Why?
|
| Language | 2 | 2013 | 7 | 0.520 |
Why?
|
| Intelligence | 2 | 2016 | 2 | 0.510 |
Why?
|
| Genetic Association Studies | 2 | 2015 | 6 | 0.510 |
Why?
|
| RNA-Binding Proteins | 7 | 2005 | 8 | 0.500 |
Why?
|
| Executive Function | 3 | 2015 | 14 | 0.500 |
Why?
|
| Hypothalamic Diseases | 5 | 2015 | 5 | 0.500 |
Why?
|
| Child Behavior Disorders | 3 | 2017 | 4 | 0.490 |
Why?
|
| Baclofen | 2 | 2012 | 2 | 0.490 |
Why?
|
| Cognition | 7 | 2016 | 79 | 0.470 |
Why?
|
| Anxiety Disorders | 3 | 2014 | 9 | 0.460 |
Why?
|
| Cholesterol | 1 | 2014 | 10 | 0.460 |
Why?
|
| Health Surveys | 3 | 2012 | 8 | 0.450 |
Why?
|
| Aged, 80 and over | 17 | 2016 | 235 | 0.450 |
Why?
|
| Imidazoles | 2 | 2017 | 12 | 0.440 |
Why?
|
| Infant, Newborn | 13 | 2017 | 52 | 0.440 |
Why?
|
| Receptor, Metabotropic Glutamate 5 | 5 | 2017 | 5 | 0.440 |
Why?
|
| Ketosis | 2 | 2005 | 3 | 0.420 |
Why?
|
| Cognitive Dysfunction | 1 | 2014 | 54 | 0.420 |
Why?
|
| Pilot Projects | 6 | 2017 | 29 | 0.410 |
Why?
|
| Mice, Knockout | 8 | 2015 | 38 | 0.410 |
Why?
|
| DNA Methylation | 6 | 2017 | 22 | 0.400 |
Why?
|
| Nervous System | 1 | 2012 | 1 | 0.400 |
Why?
|
| Seizures | 5 | 2017 | 7 | 0.390 |
Why?
|
| Psychotropic Drugs | 4 | 2017 | 6 | 0.380 |
Why?
|
| Cohort Studies | 8 | 2016 | 143 | 0.380 |
Why?
|
| DNA Mutational Analysis | 13 | 2017 | 15 | 0.380 |
Why?
|
| Apolipoproteins E | 7 | 2005 | 13 | 0.380 |
Why?
|
| Polymorphism, Genetic | 9 | 2010 | 13 | 0.380 |
Why?
|
| Obesity | 4 | 2015 | 23 | 0.370 |
Why?
|
| Piperidines | 2 | 2012 | 4 | 0.350 |
Why?
|
| Point Mutation | 4 | 2007 | 9 | 0.350 |
Why?
|
| Gene Deletion | 5 | 2013 | 9 | 0.340 |
Why?
|
| Neuroblastoma | 9 | 2006 | 9 | 0.340 |
Why?
|
| Risk Factors | 10 | 2014 | 153 | 0.340 |
Why?
|
| Genotype | 16 | 2016 | 38 | 0.330 |
Why?
|
| Peptides | 4 | 2016 | 16 | 0.320 |
Why?
|
| Down Syndrome | 3 | 2016 | 3 | 0.300 |
Why?
|
| Quality of Life | 4 | 2016 | 29 | 0.300 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2013 | 86 | 0.300 |
Why?
|
| Lithium Carbonate | 1 | 2008 | 1 | 0.300 |
Why?
|
| Biomarkers | 4 | 2017 | 51 | 0.290 |
Why?
|
| Hirschsprung Disease | 5 | 2012 | 5 | 0.290 |
Why?
|
| Autonomic Nervous System | 5 | 2011 | 6 | 0.290 |
Why?
|
| Guidelines as Topic | 1 | 2007 | 5 | 0.280 |
Why?
|
| Polymerase Chain Reaction | 4 | 2016 | 10 | 0.280 |
Why?
|
| Cyclic AMP | 7 | 1998 | 10 | 0.280 |
Why?
|
| Disease Models, Animal | 5 | 2015 | 98 | 0.280 |
Why?
|
| DNA | 9 | 2013 | 21 | 0.270 |
Why?
|
| Registries | 2 | 2017 | 20 | 0.270 |
Why?
|
| Reproducibility of Results | 5 | 2014 | 69 | 0.270 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2007 | 2 | 0.270 |
Why?
|
| Siblings | 2 | 2016 | 6 | 0.260 |
Why?
|
| Dioxoles | 1 | 2006 | 1 | 0.260 |
Why?
|
| Receptors, AMPA | 1 | 2006 | 2 | 0.260 |
Why?
|
| Glutathione Transferase | 1 | 2006 | 1 | 0.260 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2006 | 1 | 0.260 |
Why?
|
| Nicotine | 1 | 2006 | 3 | 0.260 |
Why?
|
| Child Development | 2 | 2010 | 7 | 0.260 |
Why?
|
| United States | 8 | 2017 | 174 | 0.250 |
Why?
|
| Family Health | 5 | 2010 | 5 | 0.250 |
Why?
|
| Chromosomes, Human, X | 2 | 2007 | 2 | 0.250 |
Why?
|
| DNA Repeat Expansion | 4 | 2016 | 4 | 0.250 |
Why?
|
| Receptors, Serotonin | 8 | 1993 | 8 | 0.250 |
Why?
|
| Adenylyl Cyclases | 7 | 1996 | 8 | 0.250 |
Why?
|
| Membrane Glycoproteins | 3 | 2017 | 10 | 0.240 |
Why?
|
| Administration, Oral | 3 | 2012 | 10 | 0.240 |
Why?
|
| Comorbidity | 3 | 2017 | 29 | 0.240 |
Why?
|
| Hybrid Cells | 8 | 1988 | 8 | 0.240 |
Why?
|
| Parkinson Disease | 4 | 2011 | 42 | 0.240 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2005 | 1 | 0.240 |
Why?
|
| Growth | 1 | 2005 | 1 | 0.240 |
Why?
|
| Ketone Bodies | 1 | 2005 | 1 | 0.240 |
Why?
|
| Serotonin | 8 | 2008 | 9 | 0.240 |
Why?
|
| Disease Progression | 7 | 2017 | 46 | 0.230 |
Why?
|
| Dosage Compensation, Genetic | 1 | 2005 | 1 | 0.230 |
Why?
|
| Longitudinal Studies | 6 | 2017 | 88 | 0.230 |
Why?
|
| Age of Onset | 8 | 2016 | 11 | 0.230 |
Why?
|
| Atrophy | 4 | 2017 | 9 | 0.230 |
Why?
|
| Dendritic Spines | 3 | 2013 | 4 | 0.220 |
Why?
|
| Sex Factors | 5 | 2012 | 48 | 0.220 |
Why?
|
| Double-Blind Method | 3 | 2017 | 37 | 0.220 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2013 | 19 | 0.220 |
Why?
|
| Signal Transduction | 4 | 2015 | 71 | 0.220 |
Why?
|
| Mitochondrial Proteins | 3 | 2013 | 4 | 0.220 |
Why?
|
| Forecasting | 3 | 2017 | 12 | 0.220 |
Why?
|
| Parkinsonian Disorders | 3 | 2016 | 8 | 0.210 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 3 | 2012 | 6 | 0.210 |
Why?
|
| Twins, Monozygotic | 2 | 2015 | 2 | 0.210 |
Why?
|
| Checklist | 2 | 2014 | 3 | 0.210 |
Why?
|
| Language Tests | 2 | 2013 | 2 | 0.210 |
Why?
|
| Hyperkinesis | 2 | 2013 | 4 | 0.210 |
Why?
|
| Follow-Up Studies | 6 | 2017 | 133 | 0.210 |
Why?
|
| Adrenergic alpha-Agonists | 3 | 2017 | 3 | 0.200 |
Why?
|
| Movement Disorders | 2 | 2016 | 5 | 0.200 |
Why?
|
| Epilepsies, Partial | 1 | 2002 | 1 | 0.200 |
Why?
|
| Epilepsy, Generalized | 1 | 2002 | 2 | 0.200 |
Why?
|
| Learning | 3 | 2013 | 14 | 0.200 |
Why?
|
| Carrier Proteins | 3 | 2011 | 10 | 0.190 |
Why?
|
| Antipsychotic Agents | 2 | 2017 | 7 | 0.190 |
Why?
|
| Anticonvulsants | 3 | 2010 | 7 | 0.190 |
Why?
|
| Carnitine | 1 | 2001 | 1 | 0.190 |
Why?
|
| Syndrome | 10 | 2011 | 16 | 0.180 |
Why?
|
| Biomechanical Phenomena | 3 | 2016 | 69 | 0.180 |
Why?
|
| Brain Chemistry | 5 | 2013 | 7 | 0.180 |
Why?
|
| Minocycline | 2 | 2012 | 3 | 0.180 |
Why?
|
| Enzyme Inhibitors | 2 | 2012 | 26 | 0.180 |
Why?
|
| Pedigree | 4 | 2017 | 4 | 0.180 |
Why?
|
| Abnormalities, Multiple | 3 | 2010 | 3 | 0.170 |
Why?
|
| DNA-Binding Proteins | 3 | 2011 | 21 | 0.170 |
Why?
|
| Intellectual Disability | 3 | 2016 | 5 | 0.170 |
Why?
|
| Age Factors | 4 | 2016 | 61 | 0.170 |
Why?
|
| Gene Expression Regulation | 2 | 2015 | 26 | 0.170 |
Why?
|
| Early Diagnosis | 3 | 2017 | 5 | 0.160 |
Why?
|
| Child Development Disorders, Pervasive | 3 | 2014 | 3 | 0.160 |
Why?
|
| Personality Assessment | 2 | 2012 | 2 | 0.160 |
Why?
|
| Memory Disorders | 3 | 2016 | 14 | 0.160 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 4 | 2007 | 4 | 0.160 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2017 | 5 | 0.160 |
Why?
|
| Exome | 2 | 2017 | 2 | 0.160 |
Why?
|
| Mosaicism | 4 | 2016 | 4 | 0.150 |
Why?
|
| Memory | 2 | 2013 | 20 | 0.150 |
Why?
|
| Dopamine | 2 | 2012 | 13 | 0.150 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2008 | 2 | 0.150 |
Why?
|
| Central Nervous System Stimulants | 2 | 2012 | 14 | 0.150 |
Why?
|
| Cholecystokinin | 2 | 2011 | 2 | 0.150 |
Why?
|
| Hallucinations | 2 | 2011 | 3 | 0.150 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 4 | 0.140 |
Why?
|
| Retrospective Studies | 5 | 2016 | 200 | 0.140 |
Why?
|
| Acyltransferases | 1 | 2017 | 1 | 0.140 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2017 | 6 | 0.140 |
Why?
|
| Fibroblasts | 3 | 2017 | 5 | 0.140 |
Why?
|
| Huntington Disease | 2 | 2008 | 6 | 0.140 |
Why?
|
| 2-Hydroxypropyl-beta-cyclodextrin | 1 | 2017 | 1 | 0.140 |
Why?
|
| Pyridines | 1 | 2017 | 9 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 44 | 0.140 |
Why?
|
| Applied Behavior Analysis | 1 | 2017 | 1 | 0.140 |
Why?
|
| Stakeholder Participation | 1 | 2017 | 1 | 0.140 |
Why?
|
| Databases as Topic | 1 | 2017 | 1 | 0.140 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2017 | 2 | 0.140 |
Why?
|
| Health Services Needs and Demand | 1 | 2017 | 6 | 0.140 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 19 | 0.140 |
Why?
|
| Interdisciplinary Communication | 2 | 2017 | 2 | 0.130 |
Why?
|
| Cerebellum | 4 | 2017 | 7 | 0.130 |
Why?
|
| Cell Line | 10 | 2013 | 43 | 0.130 |
Why?
|
| Educational Status | 3 | 2013 | 23 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2017 | 61 | 0.130 |
Why?
|
| Rett Syndrome | 1 | 2016 | 1 | 0.130 |
Why?
|
| Posture | 1 | 2016 | 5 | 0.130 |
Why?
|
| Tuberous Sclerosis | 1 | 2016 | 2 | 0.130 |
Why?
|
| Disability Evaluation | 1 | 2016 | 9 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 10 | 0.130 |
Why?
|
| Bile Acids and Salts | 1 | 2016 | 1 | 0.130 |
Why?
|
| Feasibility Studies | 2 | 2014 | 11 | 0.130 |
Why?
|
| Sinus Arrest, Cardiac | 1 | 2016 | 1 | 0.120 |
Why?
|
| Least-Squares Analysis | 1 | 2016 | 2 | 0.120 |
Why?
|
| Demography | 1 | 2016 | 5 | 0.120 |
Why?
|
| Placebos | 1 | 2016 | 7 | 0.120 |
Why?
|
| Anxiety | 2 | 2015 | 11 | 0.120 |
Why?
|
| Postural Balance | 1 | 2015 | 3 | 0.120 |
Why?
|
| Orexins | 1 | 2015 | 1 | 0.120 |
Why?
|
| Obesity Hypoventilation Syndrome | 1 | 2015 | 1 | 0.120 |
Why?
|
| Orexin Receptors | 1 | 2015 | 1 | 0.120 |
Why?
|
| Diseases in Twins | 2 | 2015 | 3 | 0.120 |
Why?
|
| Ganglioneuroma | 1 | 2015 | 1 | 0.120 |
Why?
|
| Ganglioneuroblastoma | 1 | 2015 | 1 | 0.120 |
Why?
|
| Parents | 2 | 2017 | 4 | 0.120 |
Why?
|
| Epigenesis, Genetic | 2 | 2016 | 10 | 0.120 |
Why?
|
| Cricetinae | 10 | 1996 | 14 | 0.120 |
Why?
|
| Primary Ovarian Insufficiency | 2 | 2012 | 2 | 0.120 |
Why?
|
| Attitude to Health | 1 | 2015 | 7 | 0.120 |
Why?
|
| Leukoencephalopathies | 1 | 2015 | 1 | 0.120 |
Why?
|
| Physicians | 2 | 2016 | 13 | 0.120 |
Why?
|
| Mothers | 1 | 2015 | 17 | 0.120 |
Why?
|
| Haplotypes | 2 | 2006 | 5 | 0.120 |
Why?
|
| Gemfibrozil | 1 | 2015 | 1 | 0.120 |
Why?
|
| PPAR alpha | 1 | 2015 | 1 | 0.120 |
Why?
|
| Astrocytes | 1 | 2015 | 5 | 0.120 |
Why?
|
| Lithium Compounds | 2 | 2012 | 2 | 0.120 |
Why?
|
| Gangliosides | 2 | 1985 | 3 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 4 | 2015 | 6 | 0.120 |
Why?
|
| Genetic Variation | 3 | 2011 | 4 | 0.110 |
Why?
|
| Gastrointestinal Diseases | 1 | 2014 | 1 | 0.110 |
Why?
|
| Nervous System Malformations | 1 | 2014 | 1 | 0.110 |
Why?
|
| Heart Diseases | 1 | 2014 | 3 | 0.110 |
Why?
|
| Exons | 4 | 2011 | 4 | 0.110 |
Why?
|
| Space Perception | 3 | 2009 | 4 | 0.110 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2012 | 6 | 0.110 |
Why?
|
| Gene Frequency | 7 | 2011 | 9 | 0.110 |
Why?
|
| Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I | 1 | 2013 | 1 | 0.110 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2013 | 3 | 0.110 |
Why?
|
| Prevalence | 2 | 2010 | 39 | 0.110 |
Why?
|
| Education | 1 | 2013 | 1 | 0.110 |
Why?
|
| Membrane Transport Proteins | 2 | 2003 | 7 | 0.100 |
Why?
|
| Nuclear Proteins | 3 | 2008 | 15 | 0.100 |
Why?
|
| Myotonic Dystrophy | 1 | 2013 | 1 | 0.100 |
Why?
|
| Language Disorders | 1 | 2013 | 2 | 0.100 |
Why?
|
| Pantothenate Kinase-Associated Neurodegeneration | 1 | 2013 | 1 | 0.100 |
Why?
|
| Iron | 1 | 2013 | 5 | 0.100 |
Why?
|
| Interneurons | 1 | 2013 | 1 | 0.100 |
Why?
|
| Haploinsufficiency | 1 | 2013 | 1 | 0.100 |
Why?
|
| Nerve Net | 1 | 2013 | 4 | 0.100 |
Why?
|
| Cells, Cultured | 4 | 2012 | 88 | 0.100 |
Why?
|
| Iron Overload | 1 | 2012 | 1 | 0.100 |
Why?
|
| Electroencephalography | 3 | 2013 | 8 | 0.100 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 6 | 0.100 |
Why?
|
| Pituitary Adenylate Cyclase-Activating Polypeptide | 2 | 2011 | 2 | 0.100 |
Why?
|
| Models, Genetic | 1 | 2012 | 3 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2012 | 7 | 0.100 |
Why?
|
| Patient Care Team | 1 | 2012 | 11 | 0.100 |
Why?
|
| Neurodegenerative Diseases | 1 | 2012 | 16 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2012 | 1 | 0.100 |
Why?
|
| Germ Cells | 1 | 2012 | 1 | 0.100 |
Why?
|
| Cutis Laxa | 1 | 2012 | 1 | 0.100 |
Why?
|
| Proton-Translocating ATPases | 1 | 2012 | 1 | 0.100 |
Why?
|
| Motor Activity | 2 | 2011 | 21 | 0.100 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2012 | 5 | 0.100 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 2 | 2011 | 2 | 0.100 |
Why?
|
| Deglutition | 1 | 2012 | 1 | 0.090 |
Why?
|
| Receptors, GABA | 1 | 2012 | 1 | 0.090 |
Why?
|
| Nootropic Agents | 1 | 2012 | 2 | 0.090 |
Why?
|
| Indans | 1 | 2012 | 2 | 0.090 |
Why?
|
| Vitamin E | 1 | 2012 | 7 | 0.090 |
Why?
|
| Antioxidants | 1 | 2012 | 10 | 0.090 |
Why?
|
| Attention | 1 | 2012 | 12 | 0.090 |
Why?
|
| Enkephalin, Leucine | 3 | 1988 | 3 | 0.090 |
Why?
|
| Pupil | 1 | 2011 | 1 | 0.090 |
Why?
|
| Eye Movements | 1 | 2011 | 2 | 0.090 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2011 | 1 | 0.090 |
Why?
|
| Peptide Fragments | 1 | 2011 | 8 | 0.090 |
Why?
|
| Melatonin | 1 | 2012 | 21 | 0.090 |
Why?
|
| Amyloid beta-Peptides | 1 | 2011 | 10 | 0.090 |
Why?
|
| Corpus Striatum | 2 | 2008 | 10 | 0.090 |
Why?
|
| Heart Rate | 2 | 2011 | 13 | 0.090 |
Why?
|
| Zinc | 1 | 2011 | 4 | 0.090 |
Why?
|
| Ion Transport | 1 | 2011 | 12 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 43 | 0.090 |
Why?
|
| Drosophila Proteins | 1 | 2011 | 1 | 0.090 |
Why?
|
| Zebrafish Proteins | 1 | 2011 | 1 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 3 | 0.090 |
Why?
|
| Cricetulus | 7 | 1986 | 8 | 0.090 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2010 | 1 | 0.090 |
Why?
|
| Carrier State | 1 | 2010 | 4 | 0.090 |
Why?
|
| Embryo, Mammalian | 3 | 2004 | 3 | 0.090 |
Why?
|
| Mutation, Missense | 2 | 2010 | 5 | 0.090 |
Why?
|
| Mitochondria | 1 | 2010 | 10 | 0.090 |
Why?
|
| Sympathetic Nervous System | 2 | 2007 | 2 | 0.080 |
Why?
|
| Gene Transfer Techniques | 2 | 2008 | 9 | 0.080 |
Why?
|
| Reaction Time | 4 | 2015 | 23 | 0.080 |
Why?
|
| Genetic Markers | 3 | 2005 | 6 | 0.080 |
Why?
|
| Introns | 2 | 2007 | 5 | 0.080 |
Why?
|
| Apolipoprotein E4 | 6 | 2005 | 26 | 0.080 |
Why?
|
| Maze Learning | 1 | 2009 | 2 | 0.080 |
Why?
|
| Reflex, Startle | 1 | 2009 | 2 | 0.080 |
Why?
|
| Sensory Gating | 1 | 2009 | 2 | 0.080 |
Why?
|
| Respiration, Artificial | 3 | 2016 | 14 | 0.080 |
Why?
|
| Chromatography, Liquid | 1 | 2009 | 1 | 0.080 |
Why?
|
| Mass Spectrometry | 1 | 2009 | 2 | 0.080 |
Why?
|
| Neurturin | 1 | 2008 | 2 | 0.080 |
Why?
|
| Neural Inhibition | 1 | 2009 | 3 | 0.080 |
Why?
|
| Cerebral Cortex | 1 | 2008 | 17 | 0.080 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2008 | 1 | 0.070 |
Why?
|
| Psychological Tests | 1 | 2008 | 3 | 0.070 |
Why?
|
| Blood Cell Count | 1 | 2008 | 2 | 0.070 |
Why?
|
| Antidepressive Agents | 1 | 2008 | 2 | 0.070 |
Why?
|
| Thyrotropin | 1 | 2008 | 2 | 0.070 |
Why?
|
| Regression Analysis | 3 | 2015 | 18 | 0.070 |
Why?
|
| Time Factors | 4 | 2011 | 159 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 3 | 2015 | 4 | 0.070 |
Why?
|
| Phosphoproteins | 1 | 1988 | 3 | 0.070 |
Why?
|
| Synapses | 1 | 2008 | 3 | 0.070 |
Why?
|
| Logistic Models | 2 | 2005 | 29 | 0.070 |
Why?
|
| Heredodegenerative Disorders, Nervous System | 1 | 2008 | 1 | 0.070 |
Why?
|
| Death, Sudden | 1 | 2008 | 2 | 0.070 |
Why?
|
| Brain Mapping | 2 | 2005 | 18 | 0.070 |
Why?
|
| Diagnosis, Differential | 4 | 2009 | 31 | 0.070 |
Why?
|
| Blotting, Western | 3 | 2012 | 19 | 0.070 |
Why?
|
| Vagus Nerve | 1 | 2007 | 3 | 0.070 |
Why?
|
| Blood Pressure | 1 | 2007 | 17 | 0.070 |
Why?
|
| Long QT Syndrome | 1 | 2007 | 2 | 0.070 |
Why?
|
| Research | 2 | 2017 | 6 | 0.070 |
Why?
|
| Mass Screening | 1 | 2007 | 9 | 0.070 |
Why?
|
| Cerebellar Ataxia | 1 | 2006 | 1 | 0.070 |
Why?
|
| Drug Eruptions | 1 | 2006 | 1 | 0.070 |
Why?
|
| Long-Term Potentiation | 1 | 2006 | 1 | 0.070 |
Why?
|
| Synaptic Transmission | 1 | 2006 | 4 | 0.070 |
Why?
|
| Central Nervous System Agents | 1 | 2006 | 2 | 0.070 |
Why?
|
| Neuronal Plasticity | 1 | 2006 | 8 | 0.070 |
Why?
|
| Frameshift Mutation | 1 | 2006 | 1 | 0.060 |
Why?
|
| Codon, Nonsense | 1 | 2006 | 1 | 0.060 |
Why?
|
| Penetrance | 1 | 2006 | 1 | 0.060 |
Why?
|
| Dermatoglyphics | 1 | 2006 | 1 | 0.060 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2006 | 1 | 0.060 |
Why?
|
| 3' Untranslated Regions | 1 | 2006 | 1 | 0.060 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factors | 1 | 2006 | 1 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2006 | 3 | 0.060 |
Why?
|
| Visual Perception | 2 | 2008 | 3 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2017 | 69 | 0.060 |
Why?
|
| Facies | 1 | 2005 | 1 | 0.060 |
Why?
|
| Amyloid | 1 | 2005 | 2 | 0.060 |
Why?
|
| Activities of Daily Living | 2 | 2017 | 88 | 0.060 |
Why?
|
| Gait Ataxia | 1 | 2005 | 1 | 0.060 |
Why?
|
| Receptors, Dopamine | 2 | 1986 | 3 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 3 | 1998 | 16 | 0.060 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 5 | 0.060 |
Why?
|
| Body Height | 1 | 2005 | 1 | 0.060 |
Why?
|
| Nutritional Requirements | 1 | 2005 | 1 | 0.060 |
Why?
|
| Body Weight | 1 | 2005 | 13 | 0.060 |
Why?
|
| Cerebral Infarction | 1 | 2005 | 6 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2016 | 102 | 0.060 |
Why?
|
| Receptors, Cholecystokinin | 1 | 2004 | 1 | 0.060 |
Why?
|
| Neurologic Examination | 3 | 2012 | 6 | 0.060 |
Why?
|
| Psychopharmacology | 1 | 2004 | 2 | 0.050 |
Why?
|
| Alprostadil | 4 | 1993 | 4 | 0.050 |
Why?
|
| Incidence | 3 | 2014 | 62 | 0.050 |
Why?
|
| Factor Analysis, Statistical | 2 | 2014 | 8 | 0.050 |
Why?
|
| Stress, Psychological | 2 | 2015 | 11 | 0.050 |
Why?
|
| Risk | 3 | 2013 | 25 | 0.050 |
Why?
|
| Videotape Recording | 1 | 2003 | 1 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2003 | 5 | 0.050 |
Why?
|
| Aging | 1 | 2004 | 77 | 0.050 |
Why?
|
| DNA Primers | 3 | 2012 | 9 | 0.050 |
Why?
|
| Base Sequence | 3 | 2012 | 18 | 0.050 |
Why?
|
| Electromyography | 2 | 2013 | 3 | 0.050 |
Why?
|
| Epilepsy, Rolandic | 1 | 2002 | 1 | 0.050 |
Why?
|
| Enkephalin, Leucine-2-Alanine | 3 | 1988 | 3 | 0.050 |
Why?
|
| Dietary Carbohydrates | 1 | 2001 | 1 | 0.050 |
Why?
|
| Hypoglycemia | 1 | 2001 | 2 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 13 | 0.050 |
Why?
|
| Dietary Fats | 1 | 2001 | 7 | 0.050 |
Why?
|
| Task Performance and Analysis | 2 | 2013 | 9 | 0.050 |
Why?
|
| Psychometrics | 2 | 2012 | 17 | 0.040 |
Why?
|
| Clonidine | 3 | 1985 | 3 | 0.040 |
Why?
|
| Health Status | 2 | 2014 | 13 | 0.040 |
Why?
|
| Prognosis | 2 | 2013 | 38 | 0.040 |
Why?
|
| Skin | 2 | 2012 | 11 | 0.040 |
Why?
|
| Memory, Short-Term | 2 | 2010 | 14 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2010 | 3 | 0.040 |
Why?
|
| Radiography | 2 | 2012 | 61 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2008 | 23 | 0.040 |
Why?
|
| Muscle Hypotonia | 1 | 2017 | 1 | 0.040 |
Why?
|
| Glycosylphosphatidylinositols | 1 | 2017 | 2 | 0.040 |
Why?
|
| Huntingtin Protein | 2 | 2008 | 4 | 0.040 |
Why?
|
| Dependovirus | 2 | 2008 | 9 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2011 | 20 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2008 | 24 | 0.030 |
Why?
|
| Fatty Acid Binding Protein 3 | 1 | 2017 | 1 | 0.030 |
Why?
|
| Hearing Loss, High-Frequency | 1 | 2017 | 1 | 0.030 |
Why?
|
| Hydroxycholesterols | 1 | 2017 | 1 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2017 | 1 | 0.030 |
Why?
|
| Calbindins | 1 | 2017 | 1 | 0.030 |
Why?
|
| Injections, Spinal | 1 | 2017 | 6 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2017 | 13 | 0.030 |
Why?
|
| Intersectoral Collaboration | 1 | 2017 | 1 | 0.030 |
Why?
|
| Parental Consent | 1 | 2017 | 1 | 0.030 |
Why?
|
| Early Medical Intervention | 1 | 2017 | 1 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 2 | 0.030 |
Why?
|
| Caregivers | 1 | 2017 | 6 | 0.030 |
Why?
|
| Organizational Objectives | 1 | 2017 | 3 | 0.030 |
Why?
|
| Rats | 3 | 2006 | 156 | 0.030 |
Why?
|
| Kinetics | 3 | 1996 | 59 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 7 | 0.030 |
Why?
|
| Pregnancy | 1 | 2017 | 44 | 0.030 |
Why?
|
| Hippocampus | 2 | 1996 | 19 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2016 | 7 | 0.030 |
Why?
|
| Dried Blood Spot Testing | 1 | 2016 | 1 | 0.030 |
Why?
|
| Breath Holding | 1 | 2016 | 1 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 53 | 0.030 |
Why?
|
| Receptors, Opioid, kappa | 1 | 1996 | 1 | 0.030 |
Why?
|
| Neuroglia | 1 | 1996 | 2 | 0.030 |
Why?
|
| Motor Skills | 1 | 2016 | 3 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 3 | 0.030 |
Why?
|
| Computers | 1 | 2015 | 3 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 5 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 3 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 3 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2015 | 2 | 0.030 |
Why?
|
| Corpus Callosum | 1 | 2015 | 2 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2015 | 6 | 0.030 |
Why?
|
| Minisatellite Repeats | 2 | 2006 | 2 | 0.030 |
Why?
|
| Lysosomes | 1 | 2015 | 1 | 0.030 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2015 | 1 | 0.030 |
Why?
|
| PPAR-beta | 1 | 2015 | 1 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2015 | 1 | 0.030 |
Why?
|
| PPAR gamma | 1 | 2015 | 2 | 0.030 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2015 | 2 | 0.030 |
Why?
|
| Tretinoin | 1 | 2015 | 2 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2015 | 5 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2015 | 5 | 0.030 |
Why?
|
| Autophagy | 1 | 2015 | 3 | 0.030 |
Why?
|
| Depression | 1 | 2015 | 27 | 0.030 |
Why?
|
| Protein Binding | 1 | 2015 | 21 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 2011 | 69 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2014 | 2 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2014 | 5 | 0.030 |
Why?
|
| Georgia | 1 | 2014 | 1 | 0.030 |
Why?
|
| beta-N-Acetylhexosaminidases | 1 | 1994 | 1 | 0.030 |
Why?
|
| Sandhoff Disease | 1 | 1994 | 1 | 0.030 |
Why?
|
| Motor Neuron Disease | 1 | 1994 | 1 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2014 | 12 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2014 | 7 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 13 | 0.030 |
Why?
|
| Maryland | 1 | 2013 | 2 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2014 | 38 | 0.030 |
Why?
|
| Movement | 1 | 2013 | 11 | 0.030 |
Why?
|
| Cell Membrane | 2 | 1984 | 35 | 0.030 |
Why?
|
| Health Policy | 1 | 2013 | 6 | 0.030 |
Why?
|
| Reference Standards | 1 | 2013 | 1 | 0.030 |
Why?
|
| Myotonin-Protein Kinase | 1 | 2013 | 1 | 0.030 |
Why?
|
| Mitochondrial Membranes | 1 | 2013 | 1 | 0.030 |
Why?
|
| Inheritance Patterns | 1 | 2013 | 1 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2013 | 3 | 0.030 |
Why?
|
| MEF2 Transcription Factors | 1 | 2013 | 1 | 0.030 |
Why?
|
| Gene Expression | 2 | 2008 | 27 | 0.030 |
Why?
|
| Dystonia | 1 | 2012 | 1 | 0.030 |
Why?
|
| Fecal Incontinence | 1 | 2012 | 1 | 0.030 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2012 | 3 | 0.030 |
Why?
|
| Urinary Incontinence | 1 | 2012 | 3 | 0.030 |
Why?
|
| Lewy Body Disease | 1 | 2012 | 4 | 0.030 |
Why?
|
| Blood Platelets | 1 | 1993 | 17 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 18 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 52 | 0.020 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 2 | 1993 | 3 | 0.020 |
Why?
|
| Colforsin | 2 | 1993 | 4 | 0.020 |
Why?
|
| Golgi Apparatus | 1 | 2012 | 1 | 0.020 |
Why?
|
| Brefeldin A | 1 | 2012 | 1 | 0.020 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2012 | 2 | 0.020 |
Why?
|
| Glycosylation | 1 | 2012 | 3 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 4 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 8 | 0.020 |
Why?
|
| Protein Transport | 1 | 2012 | 4 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 7 | 0.020 |
Why?
|
| Social Adjustment | 1 | 2012 | 2 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 15 | 0.020 |
Why?
|
| Apoptosis | 1 | 2012 | 25 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 19 | 0.020 |
Why?
|
| Gene Duplication | 1 | 2011 | 1 | 0.020 |
Why?
|
| Weight Gain | 1 | 2011 | 4 | 0.020 |
Why?
|
| Gene Knock-In Techniques | 1 | 2011 | 1 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2011 | 3 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2011 | 3 | 0.020 |
Why?
|
| DNA, Mitochondrial | 1 | 2011 | 1 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2011 | 1 | 0.020 |
Why?
|
| Arrhythmia, Sinus | 1 | 2011 | 1 | 0.020 |
Why?
|
| Monitoring, Ambulatory | 1 | 2011 | 1 | 0.020 |
Why?
|
| Respiratory Rate | 1 | 2011 | 1 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2011 | 4 | 0.020 |
Why?
|
| Social Behavior | 1 | 2011 | 5 | 0.020 |
Why?
|
| Drosophila melanogaster | 1 | 2011 | 1 | 0.020 |
Why?
|
| Embryo, Nonmammalian | 1 | 2011 | 1 | 0.020 |
Why?
|
| Epilepsies, Myoclonic | 1 | 2011 | 1 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 1 | 0.020 |
Why?
|
| Zebrafish | 1 | 2011 | 1 | 0.020 |
Why?
|
| LIM Domain Proteins | 1 | 2011 | 1 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2011 | 4 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2011 | 6 | 0.020 |
Why?
|
| Limit of Detection | 1 | 2010 | 1 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 23 | 0.020 |
Why?
|
| Electron Transport | 1 | 2010 | 1 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 2010 | 2 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2010 | 10 | 0.020 |
Why?
|
| Transfection | 3 | 1996 | 19 | 0.020 |
Why?
|
| Fathers | 1 | 2010 | 1 | 0.020 |
Why?
|
| Nuclear Family | 1 | 2010 | 2 | 0.020 |
Why?
|
| Tracheotomy | 1 | 2010 | 1 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 6 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2010 | 9 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 17 | 0.020 |
Why?
|
| Intelligence Tests | 1 | 2010 | 3 | 0.020 |
Why?
|
| Lamins | 1 | 2009 | 1 | 0.020 |
Why?
|
| Chicago | 1 | 2010 | 65 | 0.020 |
Why?
|
| Acoustic Stimulation | 1 | 2009 | 3 | 0.020 |
Why?
|
| Polysomnography | 1 | 2009 | 8 | 0.020 |
Why?
|
| Mood Disorders | 1 | 2009 | 2 | 0.020 |
Why?
|
| Calcium | 1 | 2011 | 189 | 0.020 |
Why?
|
| Rotarod Performance Test | 1 | 2008 | 1 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2008 | 9 | 0.020 |
Why?
|
| Dementia | 1 | 2009 | 32 | 0.020 |
Why?
|
| Reversal Learning | 1 | 2008 | 1 | 0.020 |
Why?
|
| Random Allocation | 1 | 2008 | 13 | 0.020 |
Why?
|
| Canada | 1 | 2008 | 6 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2008 | 3 | 0.020 |
Why?
|
| Thymus Gland | 1 | 2008 | 6 | 0.020 |
Why?
|
| Hypoxia | 1 | 2008 | 4 | 0.020 |
Why?
|
| 2-Chloroadenosine | 1 | 1988 | 1 | 0.020 |
Why?
|
| Calcimycin | 1 | 1988 | 2 | 0.020 |
Why?
|
| Protein Kinases | 1 | 1988 | 3 | 0.020 |
Why?
|
| Adenosine | 1 | 1988 | 2 | 0.020 |
Why?
|
| Immunoassay | 1 | 1988 | 3 | 0.020 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 1988 | 6 | 0.020 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2008 | 1 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2008 | 15 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 40 | 0.020 |
Why?
|
| Mutagenesis, Insertional | 1 | 2007 | 1 | 0.020 |
Why?
|
| Receptor, trkB | 1 | 2007 | 1 | 0.020 |
Why?
|
| Sleep Disorders, Intrinsic | 1 | 2007 | 1 | 0.020 |
Why?
|
| Heart Function Tests | 1 | 2007 | 1 | 0.020 |
Why?
|
| Baroreflex | 1 | 2007 | 1 | 0.020 |
Why?
|
| Catecholamines | 1 | 2007 | 2 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2007 | 2 | 0.020 |
Why?
|
| Medical History Taking | 1 | 2007 | 4 | 0.020 |
Why?
|
| Focus Groups | 1 | 2007 | 7 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2007 | 2 | 0.020 |
Why?
|
| Carbidopa | 1 | 2006 | 1 | 0.020 |
Why?
|
| Dopamine Agonists | 1 | 2006 | 5 | 0.020 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2006 | 2 | 0.020 |
Why?
|
| Benzodiazepines | 1 | 2006 | 5 | 0.020 |
Why?
|
| Levodopa | 1 | 2006 | 3 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2006 | 4 | 0.020 |
Why?
|
| Fingers | 1 | 2006 | 2 | 0.020 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor Receptors | 1 | 2006 | 1 | 0.020 |
Why?
|
| Inclusion Bodies | 1 | 2006 | 2 | 0.020 |
Why?
|
| Cell Death | 1 | 2006 | 7 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2006 | 9 | 0.020 |
Why?
|
| Glucosamine | 1 | 1986 | 1 | 0.020 |
Why?
|
| Tunicamycin | 1 | 1986 | 1 | 0.020 |
Why?
|
| Receptors, Neurotransmitter | 1 | 1986 | 1 | 0.020 |
Why?
|
| Alkaloids | 1 | 1986 | 3 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1986 | 5 | 0.020 |
Why?
|
| Glycoproteins | 1 | 1986 | 13 | 0.020 |
Why?
|
| Cholera Toxin | 1 | 1985 | 1 | 0.020 |
Why?
|
| Chromatography, Thin Layer | 1 | 1985 | 1 | 0.020 |
Why?
|
| G(M1) Ganglioside | 1 | 1985 | 1 | 0.020 |
Why?
|
| G(M2) Ganglioside | 1 | 1985 | 1 | 0.020 |
Why?
|
| Autopsy | 1 | 2005 | 12 | 0.020 |
Why?
|
| Vascular Diseases | 1 | 2005 | 3 | 0.010 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2005 | 3 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2005 | 16 | 0.010 |
Why?
|
| Clergy | 1 | 2005 | 1 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2005 | 7 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2005 | 24 | 0.010 |
Why?
|
| Stroke | 1 | 2005 | 31 | 0.010 |
Why?
|
| CHO Cells | 2 | 1996 | 4 | 0.010 |
Why?
|
| Apomorphine | 1 | 1984 | 1 | 0.010 |
Why?
|
| Prostaglandins E | 1 | 1984 | 1 | 0.010 |
Why?
|
| Spiperone | 1 | 1984 | 1 | 0.010 |
Why?
|
| Dopamine Agents | 1 | 2004 | 1 | 0.010 |
Why?
|
| California | 1 | 2004 | 9 | 0.010 |
Why?
|
| Embryonic and Fetal Development | 1 | 2003 | 1 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2003 | 1 | 0.010 |
Why?
|
| Guanylyl Imidodiphosphate | 1 | 1983 | 1 | 0.010 |
Why?
|
| Ribonucleotides | 1 | 1983 | 1 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1983 | 5 | 0.010 |
Why?
|
| Clone Cells | 1 | 1983 | 4 | 0.010 |
Why?
|
| Patient Selection | 1 | 2003 | 8 | 0.010 |
Why?
|
| Epidemiologic Studies | 1 | 2003 | 4 | 0.010 |
Why?
|
| Enkephalins | 1 | 1983 | 1 | 0.010 |
Why?
|
| Prostaglandins | 1 | 1983 | 1 | 0.010 |
Why?
|
| Urban Population | 1 | 2003 | 10 | 0.010 |
Why?
|
| Cations | 1 | 1983 | 3 | 0.010 |
Why?
|
| Linear Models | 1 | 2003 | 19 | 0.010 |
Why?
|
| Narcotics | 1 | 1983 | 2 | 0.010 |
Why?
|
| Ascorbic Acid | 1 | 1983 | 13 | 0.010 |
Why?
|
| Apolipoprotein E2 | 1 | 2002 | 1 | 0.010 |
Why?
|
| Apolipoprotein E3 | 1 | 2002 | 2 | 0.010 |
Why?
|
| Mental Recall | 1 | 2002 | 9 | 0.010 |
Why?
|
| Reference Values | 1 | 2002 | 21 | 0.010 |
Why?
|
| Cerebellar Cortex | 1 | 2002 | 1 | 0.010 |
Why?
|
| Cerebellar Diseases | 1 | 2002 | 1 | 0.010 |
Why?
|
| Cerebral Ventricles | 1 | 2002 | 4 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2000 | 26 | 0.010 |
Why?
|
| Prospective Studies | 1 | 1997 | 137 | 0.010 |
Why?
|
| Phospholipase D | 1 | 1996 | 1 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1996 | 2 | 0.010 |
Why?
|
| Type C Phospholipases | 1 | 1996 | 2 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1996 | 5 | 0.010 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 1996 | 5 | 0.010 |
Why?
|
| Neurofilament Proteins | 1 | 1996 | 4 | 0.010 |
Why?
|
| Antibodies | 1 | 1996 | 10 | 0.010 |
Why?
|
| Tyrosine | 1 | 1994 | 1 | 0.010 |
Why?
|
| Hexosaminidase A | 1 | 1994 | 1 | 0.010 |
Why?
|
| Hexosaminidase B | 1 | 1994 | 1 | 0.010 |
Why?
|
| Serine | 1 | 1994 | 2 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1994 | 4 | 0.010 |
Why?
|
| Protein Structure, Secondary | 1 | 1994 | 6 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1994 | 20 | 0.010 |
Why?
|
| Glioma | 1 | 1993 | 1 | 0.010 |
Why?
|
| 8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 1993 | 1 | 0.010 |
Why?
|
| Glucose | 1 | 1993 | 3 | 0.010 |
Why?
|
| Lysergic Acid | 1 | 1993 | 1 | 0.010 |
Why?
|
| Paroxetine | 1 | 1993 | 1 | 0.010 |
Why?
|
| Platelet Count | 1 | 1993 | 3 | 0.010 |
Why?
|
| Biological Transport | 1 | 1993 | 12 | 0.010 |
Why?
|
| Receptors, Opioid | 1 | 1986 | 1 | 0.000 |
Why?
|
| Swainsonine | 1 | 1986 | 1 | 0.000 |
Why?
|
| Receptors, Opioid, delta | 1 | 1986 | 1 | 0.000 |
Why?
|
| Receptors, sigma | 1 | 1986 | 1 | 0.000 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1986 | 26 | 0.000 |
Why?
|